The Middle East and Africa ADHD Therapeutics Market is expected to reach USD 1.42 billion by 2027 from USD 0.91 billion in 2022, growing at a CAGR of 9.31% during the forecast period.
The healthcare industry is expected to be ruled by technology-driven innovation in the future. As a result, extensive research is being undertaken in every healthcare market sector, with precision medicine serving as the focal point.
ADHD children are more likely to develop a range of additional issues, such as clinical depression. In addition, due to their warped lifestyle and inability to control their urges, these children may develop long-term psychiatric disorders. As a result, it's vital to create effective ADHD therapies for children and teenagers. Furthermore, the growing focus of the medical community on the treatment of mental illnesses is expected to boost market growth.
The prevalence and incidence of attention-deficit hyperactivity disorder among adults and children in MEA are estimated to accelerate the market's growth during the forecast period. Furthermore, countries such as the United Arab Emirates (UAE) and Kuwait, where key companies are focusing on research and development in the treatment of attention deficit hyperactivity disorder (ADHD), are expected to drive the Therapeutics for attention deficit hyperactivity disorder (ADHD) in MEA during the forecast period.
However, prescriptions are limited based on a patient's medical condition due to many contraindications and harmful effects of ADHD drugs, which is expected to slow revenue growth.
This research report on the MEA ADHD therapeutics market has been segmented and sub-segmented into the following categories:
By Education Or Training:
During the forecast period, the demand for ADHD drugs in the MEA is expected to expand. The healthcare industry is working hard to provide viable treatment options for ADHD in children and adolescents. Because of the detrimental implications of ADHD, medical experts have decided to focus their efforts on finding new treatment alternatives.
A thorough examination of the regional market for ADHD therapies uncovers a host of factors that have influenced regional demand. In the UAE and Kuwait, attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by debilitating and pervasive impulsivity, hyperactivity, and inattention symptoms.
KEY MARKET PLAYERS:
Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.) are a few of the prominent companies in the MEA ADHD therapeutics market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]